Advances in Cardiovascular Risk Reduction
Friday, May 8, 2015
NYU Langone Medical Center
550 First Avenue
Alumni Hall, Farkas Auditorium
New York, NY 10016
*After 12pm on May 6, 2015, only onsite registration is available, provided the course has not reached capacity. Onsite registrants will incur an additional $20 fee. Registration is non-transferable.
Arthur Z. Schwartzbard, MD, FACC
Edward Fisher, PhD, MPH, MD
Ira J. Goldberg, MD
Lawrence Phillips, MD
James Underberg, MS, MD
Co-organized by the Division of Cardiology and the Division of Endocrinology, Diabetes, and Metabolism
Full Fee: $175
Reduced Fee**: $60
NYU Langone Faculty and Staff: $60 (must provide valid NYU Langone ID)
Residents and Fellows***: Waived
**Reduced fee applies to NYU School of Medicine alumni, former residents and fellows; physicians employed by the Department of Veterans Affairs Medical Center; full-time active military personnel; nurse practitioners; retired physicians; and all other non-physician healthcare professionals. ***To register at the waived fellow rate, you must submit a letter on official stationery from the Chief of Service stating that you are a fellow in a full-time approved training program to email@example.com.
Internists, family practitioners, cardiologists, general practice, endocrinologists, nurse practitioners, and dietitians with an interest in the prevention of heart disease
This one-day course will cover state-of-the-art management of patients with cardiovascular risk factors, with a focus on prevention. This year’s program includes topics such as PCSK9, Imaging in Atherosclerosis, APOC3, Triglycerides and Cardiovascular Disease Risk, GLP1 and SGLT2 inhibitors in the treatment of diabetes, pharmaceutical therapies for weight loss, and updates on the treatment of platelet disorders and ischemia.
Each year this course includes a researchoriented presentation that highlights bench-to-bedside relevance. This year the featured research-oriented presentation will focus on the latest in atherosclerosis laboratory research.
Statement of Need
This year’s program addresses practice gaps in the treatment of diabetes, obesity, atherosclerosis, coronary artery disease and dyslipidemia. Recent studies have made it necessary to update physicians on:
- The effects of personalized diabetic care in preventing health complications and improving the quality of life for millions of Americans
- New therapies, including GLP1 and SGLT2 inhibitors, that offer novel therapeutic strategies for the treatment of diabetes
- Several new drugs that were recently made available in the treatment of obesity
- Imaging modalities that are available for assessing atherosclerosis risk as well as treatment of atherosclerosis
- Current concepts (low dose aspirin therapy) and new agents in anti-platelet therapy
- The critical role PCSK9 plays in modulating LDL levels
- The potential for APOC3 therapies, as a potential new class of drugs, to protect against coronary artery disease
After participating in this activity, clinicians should be able to:
- Discuss how GLP1 and SGLT2 inhibitors can be utilized to treat diabetics
- Describe current and novel agents for obesity treatment
- Incorporate noninvasive testing modalities for atherosclerosis in assessing risk for development as well as identification of subclinical disease
- Summarize the role of anti-platelet agents in preventing cardiovascular events and their efficacy and safety in light of recent clinical trials
- Describe how, PCSK9 modulates LDL levels and how PCSK9 expression is affected by statin treatment
- Describe recent APOC3 studies and how the results of these studies have elucidated the role of APOC3 on triglyceride levels and CAD risk
- Describe current mechanisms of atherosclerosis including new factors regulating LDL clearance
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the NYU Post-Graduate Medical School, the NY Chapter American College of Physicians and the Northeast Lipid Association. The NYU Post-Graduate Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The NYU Post-Graduate Medical School designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to request a refund, you must click here to complete and submit our online refund form no later than 14 days prior to the first day of the course. An administrative fee of $75 will be deducted from your refund. Cancellations or no-shows after this date are not eligible for a refund. Fax and email cancellations are not accepted.
Course Cancellation Policy
In the unusual circumstance that this course is cancelled, two weeks' notice will be given and tuition will be refunded in full. The NYU Post-Graduate Medical School is not responsible for any airfare, hotel or other costs incurred.